Post by
Noteable on Dec 22, 2022 10:52am
Merck USA (MSD) signs US$ 9.3 Billion bio-buck deal
Conversely ONCY is seeking a hard cash upfront deal.
https://www.biospace.com/article/releases/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer/
Comment by
fox7mf on Dec 22, 2022 11:12am
Oncy is ph3 ready for multiple indications...with accelerated approval or priority review, they could jump all the way to ph4 in short order. Their deal with BP will be all upfront & big...save the biobuck deals for lesser advanced biotechs.
Comment by
Buckhenry on Dec 22, 2022 1:53pm
will buy more at $1.50.....
Comment by
Noteable on Dec 23, 2022 1:31pm
Meanwhile ONCY's pelareorep is a Phase 3 ready immune molecule platform that appears entirely ready for the reformed accelerated approval program. https://endpts.com/back-again-merck-willing-to-dole-out-more-than-9b-for-keluns-adcs/